Executive Intelligence
Life Sciences Reports
Regulatory, funding, leadership, market and commercial updates selected for life-science executives.
Guidance: MHRA Strategy to 2030: What it means for you
A series of explainers to help you understand the parts of the MHRA Strategy to 2030 most relevant to you, and what they mean in practice.
Read full reportGuidance: MHRA Strategy to 2030: What it means for you
A series of explainers to help you understand the parts of the MHRA Strategy to 2030 most relevant to you, and what they mean in practice.
Read full reportGuidance: MHRA Strategy to 2030: What it means for you
A series of explainers to help you understand the parts of the MHRA Strategy to 2030 most relevant to you, and what they mean in practice.
Read full reportMHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines
The Medicines and Healthcare products Regulatory Agency (MHRA) has set out ambitious plans to translate cutting-edge scientific and technological innovation into better health outcomes for patients across all four nations of the UK, in its 2030 Strategy published today.
Read full reportMHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines
The Medicines and Healthcare products Regulatory Agency (MHRA) has set out ambitious plans to translate cutting-edge scientific and technological innovation into better health outcomes for patients across all four nations of the UK, in its 2030 Strategy published today.
Read full reportMHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines
The Medicines and Healthcare products Regulatory Agency (MHRA) has set out ambitious plans to translate cutting-edge scientific and technological innovation into better health outcomes for patients across all four nations of the UK, in its 2030 Strategy published today.
Read full reportMHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines
The Medicines and Healthcare products Regulatory Agency (MHRA) has set out ambitious plans to translate cutting-edge scientific and technological innovation into better health outcomes for patients across all four nations of the UK, in its 2030 Strategy published today.
Read full reportCorporate report: MHRA Strategy 2030
How the MHRA Strategy to 2030 sets out to deliver health and prosperity for all, through scientific excellence.
Read full reportCorporate report: MHRA Strategy 2030
How the MHRA Strategy to 2030 sets out to deliver health and prosperity for all, through scientific excellence.
Read full reportMHRA authorises Onswik (insulin efsitora alfa) for adults with type 2 diabetes
The new treatment option is administered once weekly, potentially reducing the number of injections from up to 365 a year to 52 for some adults with type 2 diabetes.
Read full reportContinuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based filter membranes DSI/2026/014
Continuous renal replacement therapy (CRRT) is used for managing severe acute kidney injury and fluid overload. Published evidence has shown that caspofungin can bind to polyacrylonitrile (PAN)-based membranes used in CRRT which may result in ineffective antifungal treatment.
Read full reportClass 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/42
Norgine Pharmaceuticals Limited is recalling the batches listed in the table due to risk of particulate matter being present in the product identified during routine stability investigations.
Read full reportNova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption DSI/2026/013
Nova Biomedical has identified quality issues affecting specified lots of StatStrip ketone test strips. The affected lots have been associated with quality-control (QC) failures and Nova Biomedical has initiated a recall, advising that these lots should not be used.
Read full reportField Safety Notices for October 2026
Field Safety Notices for October 2026
Read full reportField Safety Notices: 8 -12 June 2026
List of Field Safety Notices for 8-12 June 2026
Read full reportMeeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 October 2026
CVMP opinions on veterinary medicinal productsThe Committee adopted a positive opinion, in exceptional circumstances, for a marketing authorisation for Bovilis Lumpyvax (lumpy…
Read full reportGuidance: MHRA Real-World Evidence: knowledge and guidance
Supporting guidance, publications and resources on the use of real-world data (RWD) and real-world evidence (RWE) in regulatory decision-making for medicines and medical devices in the UK.
Read full reportClinical trial applications advice pilot becomes permanent
The Accelerating Clinical Trials in the EU (ACT EU) advice pilot, which helps sponsors prepare clinical trial applications, will become a permanent initiative from January 2027…
Read full reportGuidance: Pneumococcal Vaccine Factsheet – Information for Patients, Parents and Carers
Patient factsheet providing information on pneumococcal disease and pneumococcal vaccination.
Read full reportMHRA approves catumaxomab to treat cancer-related fluid build-up in the abdomen
As with all licensed medicines, the MHRA will keep the safety and effectiveness of catumaxomab under close review.
Read full reportGovernment backs recommendations of NHS doctors-led AI Commission
Ministers back independent Commission's blueprint in full, while the MHRA's AI Airlock opens its next phase,
Read full reportGuidance: What the National Commission’s recommendations mean for you
How new recommendations could make healthcare AI safer, clearer and fairer for patients, professionals, providers and developers across the UK.
Read full reportGuidance: AI Airlock Phase 3 application
The call for applications for phase 3 of the AI Airlock is now open.
Read full reportPolicy paper: Government Response to the National Commission’s Recommendations on the Regulation of AI in Healthcare.
The government's response published on the 6 October 2026 to provide clarity to stakeholders on how the government intends to take forward the recommendations made by the independent National Commission.
Read full report